FIG 7.
Quantification of vpu/env mRNA accurately assesses bNab efficacy in HIV-1-infected humanized mice. (A) Treatment scheme. (B and C) bNab treatment suppresses HIV-1 replication. MISTRG-6-15 mice engrafted with human cord blood CD34+ cells were infected with HIVBa-L. Plasma viral load was measured at days 14 and 21 postinfection. (C and D) Quantification of cell-associated gag and vpu/env RNA. In panel C, cell-associated HIV-1 RNA was measured in spleens (circle) or lymph nodes (triangle) of control or bNab-treated mice. In panel D, lungs (triangle) or livers (circle) were collected for the measurement of cell-associated HIV-1 RNA. (B) P values were calculated by paired t test. (C, D, and E) P values were calculated by the Mann-Whitney U test. *, P < 0.05; **, P < 0.01.